The size of the global bladder cancer therapeutics market is expected to reach USD 320.8 million by 2024 from USD 240.22 million in 2019, growing at a CAGR of 4.95% during the forecast period 2019 - 2024.
The increasing incidence of tumors, innovations of drugs for treatment and advances in technology. As this cancer is more common in adults over 50 years, the increase in the geriatric population also contributes to the growth of the market. In addition, government initiatives increased awareness of bladder cancer and available treatments, as well as progressive health services associated with increased spending on health care also boost the global Bladder Cancer Therapeutics Market. Since cancer is an asymptomatic disease in the initial stage, it requires an accurate diagnosis at an early stage.
Advance technology, new treatments, advanced healthcare services and increasing knowledge about the bladder cancer therapies among the people, launch of new novel drugs and acceptance of effective diagnostic tools and also rise in healthcare expenditure are the factors that drive the global bladder cancer therapeutics market growth.
Factors like less availability of various treatment options, an increase in healthcare services, and increasing knowledge about all kinds of cancers are the facts that are hindering the global bladder cancer therapeutics market growth. High costs that are associated with the devices may hamper the growth.
Strict regulatory policies, poorly developed healthcare infrastructure, and limited adoption of advanced cancer therapies hinder the growth.
Launch of new products, rise in the investments on research and development and the manufacturing demand increases poses differentiable growth opportunities in the global bladder cancer therapeutics market.
The challenges that are facing by the bladder cancer therapeutics market are people in rural areas are less aware of the treatment procedures available and also less availability of skilled persons in diagnostic centers.
Key happenings in the global bladder cancer therapeutics market in the recent past:
REPORT COVERAGE
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2018 – 2024 |
|
Base Year |
2018 |
|
Forecast Period |
2019 – 2024 |
|
Segments Analysed |
By Type, Treatment, and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Analysed |
North America, Europe, APAC, Latin America, Middle East & Africa |
|
Companies Analysed |
Sanofi S.A., Novartis AG, Pfizer Inc., GlaxoSmithKline plc, Eli Lilly and Company, AstraZeneca plc, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd. And Celgene Corporation |
This research report on the Global Bladder Cancer Therapeutics Market has been segmented and sub-segmented into the following categories and calculated market size and forecast for each segment until 2024.
Bladder Cancer Therapeutics Market - By Type:
Based on the type, the transitional cell bladder segment holds the market share in the market by owing to improving healthcare infrastructures in both developed and developing countries.
Bladder Cancer Therapeutics Market - By Treatment:
Based on the treatment type, the Chemotherapy segment holds the highest market share due to the availability of a large number of chemotherapy drugs in the market.
Regional Insights
North America commands the major market share of 41.0% of the global bladder cancer therapeutics market in 2018, whereas Asia-Pacific is expected to grow at the highest CAGR of 5.68% during the forecast period 2019 - 2024.
North America leads the world market for bladder cancer. Most of the region is attributed to an increased incidence of bladder cancer, innovative healthcare solutions, advanced healthcare infrastructure and growing concern about bladder problems. Europe represents the second largest market share. The global bladder cancer market in Asia-Pacific is expected to experience strong growth. This increase is mainly due to the growing awareness of bladder diseases and innovative diagnostic and treatment options. The main market players believe that Asian countries are lucrative markets for bladder cancer and are making significant investments, leading to market growth.
Companies leading the Global Bladder Cancer Therapeutics Market profiled in the report are:
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Type
5.1.1 Transitional Cell Bladder Cancer
5.1.2 Non Muscle Invasive/Superficial Bladder Cancer
5.1.3 Invasive Bladder Cancer
5.1.4 Squamous Cell Bladder Cancer
5.1.5 Adenocarcinoma of the Bladder
5.1.6 Rare Bladder Cancers
5.2 By Treatment
5.2.1 Surgery
5.2.1.1 Transurethral Bladder Tumor Resection (TURBT)
5.2.1.2 Cystectomy
5.2.1.3 Urinary Diversion
5.2.2 Chemotherapy
5.2.3 Immunotherapy
5.2.4 Radiation Therapy
5.2.5 Intravesical Therapy
6. Geographical Analysis
6.1 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.2 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.3 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 South Korea
6.3.6 Australia
6.4 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.5 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
8.Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9.Market Leaders' Analysis
9.1 Sanofi S.A. (France)
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Financial analysis
9.1.4 Recent Developments
9.1.5 SWOT analysis
9.1.6 Analyst View
9.2 Novartis AG (Switzerland)
9.3 Pfizer Inc. (U.S.)
9.4 GlaxoSmithKline plc (U.K.)
9.5 Eli Lilly and Company (U.S.)
9.6 AstraZeneca plc (U.K.)
9.7 Bristol-Myers Squibb (U.S.)
9.9 F. Hoffmann-La Roche Ltd. (Switzerland)
9.10 Celgene Corporation (U.S.)
10.Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11.Expert Opinions
11.1 Market Outlook
11.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Feb 2020
Download Sample
Feb 2020
Download Sample
Feb 2020
Download Sample
Feb 2020
Download Sample
Feb 2020
Download Sample
